vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Goosehead Insurance, Inc. (GSHD). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $93.1M, roughly 1.5× Goosehead Insurance, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 8.6%, a 26.8% gap on every dollar of revenue. On growth, Goosehead Insurance, Inc. posted the faster year-over-year revenue change (23.1% vs 18.4%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 9.2%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Goosehead Insurance is a U.S.-based personal lines insurance agency that offers a wide range of coverage products including auto, home, renters, flood, and specialty insurance. It partners with hundreds of insurance carriers to provide clients with tailored, cost-effective coverage options, operating via corporate locations and a national franchise network for independent agents.
ADMA vs GSHD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $93.1M |
| Net Profit | $49.4M | $8.0M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 16.1% |
| Net Margin | 35.5% | 8.6% |
| Revenue YoY | 18.4% | 23.1% |
| Net Profit YoY | -55.9% | 204.0% |
| EPS (diluted) | $0.20 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $93.1M | ||
| Q4 25 | $139.2M | $105.3M | ||
| Q3 25 | $134.2M | $90.4M | ||
| Q2 25 | $122.0M | $94.0M | ||
| Q1 25 | $114.8M | $75.6M | ||
| Q4 24 | $117.5M | $93.9M | ||
| Q3 24 | $119.8M | $78.0M | ||
| Q2 24 | $107.2M | $78.1M |
| Q1 26 | — | $8.0M | ||
| Q4 25 | $49.4M | $12.4M | ||
| Q3 25 | $36.4M | $7.9M | ||
| Q2 25 | $34.2M | $5.2M | ||
| Q1 25 | $26.9M | $2.3M | ||
| Q4 24 | $111.9M | $14.9M | ||
| Q3 24 | $35.9M | $7.6M | ||
| Q2 24 | $32.1M | $6.2M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | 16.1% | ||
| Q4 25 | 45.1% | 29.4% | ||
| Q3 25 | 38.0% | 23.5% | ||
| Q2 25 | 35.1% | 16.7% | ||
| Q1 25 | 30.4% | 8.8% | ||
| Q4 24 | 32.6% | 29.7% | ||
| Q3 24 | 33.1% | 21.1% | ||
| Q2 24 | 36.6% | 19.7% |
| Q1 26 | — | 8.6% | ||
| Q4 25 | 35.5% | 11.8% | ||
| Q3 25 | 27.1% | 8.7% | ||
| Q2 25 | 28.1% | 5.5% | ||
| Q1 25 | 23.4% | 3.1% | ||
| Q4 24 | 95.2% | 15.8% | ||
| Q3 24 | 30.0% | 9.7% | ||
| Q2 24 | 29.9% | 7.9% |
| Q1 26 | — | $0.19 | ||
| Q4 25 | $0.20 | $0.48 | ||
| Q3 25 | $0.15 | $0.29 | ||
| Q2 25 | $0.14 | $0.18 | ||
| Q1 25 | $0.11 | $0.09 | ||
| Q4 24 | $0.45 | $0.58 | ||
| Q3 24 | $0.15 | $0.29 | ||
| Q2 24 | $0.13 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $25.7M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $-121.3M |
| Total Assets | $624.2M | $392.8M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $25.7M | ||
| Q4 25 | $87.6M | $34.4M | ||
| Q3 25 | $61.4M | $51.6M | ||
| Q2 25 | $90.3M | $92.4M | ||
| Q1 25 | $71.6M | $70.2M | ||
| Q4 24 | $103.1M | $54.3M | ||
| Q3 24 | $86.7M | $47.5M | ||
| Q2 24 | $88.2M | $23.6M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | $289.5M | ||
| Q3 25 | $72.4M | $290.0M | ||
| Q2 25 | — | $289.8M | ||
| Q1 25 | — | $290.3M | ||
| Q4 24 | $72.3M | $82.3M | ||
| Q3 24 | — | $84.6M | ||
| Q2 24 | — | $87.0M |
| Q1 26 | — | $-121.3M | ||
| Q4 25 | $477.3M | $-95.5M | ||
| Q3 25 | $431.2M | $-105.0M | ||
| Q2 25 | $398.3M | $-78.6M | ||
| Q1 25 | $373.4M | $-88.5M | ||
| Q4 24 | $349.0M | $43.9M | ||
| Q3 24 | $231.9M | $58.3M | ||
| Q2 24 | $188.3M | $39.8M |
| Q1 26 | — | $392.8M | ||
| Q4 25 | $624.2M | $414.9M | ||
| Q3 25 | $568.7M | $403.6M | ||
| Q2 25 | $558.4M | $436.6M | ||
| Q1 25 | $510.6M | $412.6M | ||
| Q4 24 | $488.7M | $397.7M | ||
| Q3 24 | $390.6M | $358.1M | ||
| Q2 24 | $376.4M | $338.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 1.87× | ||
| Q3 24 | — | 1.45× | ||
| Q2 24 | — | 2.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $91.8M | ||
| Q3 25 | $13.3M | $24.2M | ||
| Q2 25 | $21.1M | $28.9M | ||
| Q1 25 | $-19.7M | $15.5M | ||
| Q4 24 | $50.2M | $71.5M | ||
| Q3 24 | $25.0M | $28.1M | ||
| Q2 24 | $45.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $86.1M | ||
| Q3 25 | $-1.1M | $23.7M | ||
| Q2 25 | $18.7M | $27.2M | ||
| Q1 25 | $-24.4M | $14.9M | ||
| Q4 24 | $47.5M | $70.6M | ||
| Q3 24 | $24.0M | $28.0M | ||
| Q2 24 | $43.6M | $18.6M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 81.8% | ||
| Q3 25 | -0.8% | 26.2% | ||
| Q2 25 | 15.3% | 28.9% | ||
| Q1 25 | -21.2% | 19.7% | ||
| Q4 24 | 40.4% | 75.1% | ||
| Q3 24 | 20.0% | 35.9% | ||
| Q2 24 | 40.7% | 23.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 5.4% | ||
| Q3 25 | 10.7% | 0.5% | ||
| Q2 25 | 2.0% | 1.8% | ||
| Q1 25 | 4.1% | 0.8% | ||
| Q4 24 | 2.3% | 1.0% | ||
| Q3 24 | 0.9% | 0.1% | ||
| Q2 24 | 1.9% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 7.38× | ||
| Q3 25 | 0.36× | 3.06× | ||
| Q2 25 | 0.62× | 5.61× | ||
| Q1 25 | -0.73× | 6.61× | ||
| Q4 24 | 0.45× | 4.82× | ||
| Q3 24 | 0.70× | 3.72× | ||
| Q2 24 | 1.42× | 3.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
GSHD
| Renewal Royalty Fees (2) | $43.6M | 47% |
| Renewal Commissions (1) | $18.2M | 20% |
| Contingent Commissions (1) | $10.7M | 11% |
| New Business Royalty Fees (2) | $7.9M | 8% |
| New Business Commissions (1) | $7.5M | 8% |
| Other | $3.7M | 4% |
| Initial Franchise Fees (2) | $1.6M | 2% |
